Pharma BD Deal Intelligence
A shell-company reverse merger that gave Astralis public-market cash — then its only asset, Psoraxine, missed its Phase II endpoint in 2005 and the stock collapsed 48%, with no recovery found in the public record.
Full analysis, sources & comparables →Astralis won shareholder approval for a reverse takeover by real-estate shell Hercules Development Group valued at ~$110M in stock; lead product Psoraxine was…
Weeks after the Exchange, SkyePharma agreed to make a total equity investment in the Company of up to $20 million and to provide all development,…
Astralis's Psoraxine missed its Phase II primary efficacy endpoint, failing to show statistically significant PASI improvement vs placebo; the stock fell…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Below $250M; reverse-merger structure into psoriasis biotech. Marginal inclusion.
A shell-company reverse merger that gave Astralis public-market cash — then its only asset, Psoraxine, missed its Phase II endpoint in 2005 and the stock collapsed 48%, with no recovery found in the public record.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hercules Development Group / Astralis LLC (this deal) | 2001 | $111M | 9 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals